Hello everyone and welcome to At Bairns. I'm Andy Surwerp.

And welcome to our guest Albert Borla, CEO of Pfizer. Albert, nice to see you.

Very nice to see you, Anthony. Thank you for having me.

So let's start off with your recent acquisition, Cgen, and I know that you've gotten regulatory approval for that.

This is a key driver you say for your business going forward. Talk to us about that.

Yes, Sizen offers a tremendous opportunity for the cancer patients.

And they have a tremendous technology, ADC, and they are a very, very good company, particularly since we announced the acquisition, they have presented data

that they are stunning. They got standing ovation from scientists when they presented those data.

And season in the Heisen-Fizer, together, one plus one, I think, equals three.

We should be able to provide resources that they didn't have before.

So we should be able to do things that they wouldn't be able to do before alone. And of course, we wouldn't be able to provide resources that they didn't have before. So we should be able to do things that they wouldn't be able to do before a loan.

And of course, we wouldn't be able to do it before a loan.

Right.

And operationally, how much do you see this contributing to, say, the P&L going forward?

Oh, it's going to be a tremendous opportunity for growth for us.

This is an acquisition

right now we forecast that will exceed $10 billion by year 2030 in terms of revenues and right

now we have they are around less than three in year 2023 so i think growing all these years

by by that much offers significant opportunities for growth.

Right.

At the recent J.P. Morgan conference, you talked about this being a year for execution for

Pfizer and talked about paying down debt, maybe a stock buyback, maybe no more big MNA. Can you speak to that?

...